Akeso, Inc.: Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been dosed in a Phase II clinical ...
Yahoo Finance

All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three ...

HONG KONG, Dec. 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the successful inclusion of all five of the Company's self-developed innovative drugs into the ...

Akeso, Inc.: Phase II Trial of Cadonilimab (PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan ...
Nasdaq

Akeso, Inc. Raises HK$1.924 Billion Through Share Placement

Akeso, Inc. (HK:9926) has released an update. Akeso, Inc. has successfully completed a placement of 31.7 million new shares, raising approximately HK$1.924 billion. The shares were placed with ...
Nasdaq

Akeso, Inc.’s New Cancer Drug Wins China Approval

Akeso, Inc. (HK:9926) has released an update. Akeso, Inc. has announced that its novel drug ivonescimab, designed for advanced lung cancer patients who’ve progressed after standard EGFR TKI treatments ...
Yahoo Finance

Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment ...

HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine ...
Yahoo

Summit Therapeutics in up to $5 billion licensing deal for Akeso's cancer therapy

Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) - Summit Therapeutics Inc said on Tuesday it would license China-based Akeso Inc's experimental cancer therapy in a deal ...
Nature

Akeso, Inc

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen by an independent group of researchers. The Nature Index provides absolute Count of ...
Benzinga.com

Why Is Summit Therapeutics Stock Soaring On Wednesday?

Summit Therapeutics Inc.'s (NASDAQ:SMMT) partner, Akeso, Inc., released topline data from the Phase 3 HARMONi-6/K112-306 trial on Wednesday. The trial is evaluating ivonescimab in combination with ...
manilatimes

Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance

HONG KONG, March 16, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has ...
Business Wire

Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody

MENLO PARK, Calif.--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that we have completed the closing of our previously announced ...
Nature

Akeso, Inc

The Nature Index tracks primary research articles from 178 applied, health, natural and social sciences journals, across many different publishers, chosen by an independent group of researchers. The ...